Stock 609 ABIONYX PHARMA
Add to a list
To use this feature you must be a member
Log inSign up

News ABIONYX Pharma Börse Stuttgart

Equities

609

FR0012616852

Market Closed - Börse Stuttgart
Other stock markets
 10:01:47 2024-06-07 am EDT 		5-day change 1st Jan Change
1.146 EUR -1.72% Intraday chart for ABIONYX Pharma -1.72% -36.40%
Mar. 14 Abionyx Pharma: to benefit from a 1ME grant from Bpifrance CF
Mar. 11 Abionyx: reduced net loss in 2023 CF

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
ABIONYX Pharma Provides an Update on Its Activity and Cash Position for the 1st Quarter 2024
BU
ABIONYX Pharma: Availability of the Universal Registration Document for the Year 2023
BU
Abionyx Pharma: to benefit from a 1ME grant from Bpifrance
CF
ABIONYX Pharma - Bpifrance Supports the Development of CER-001 in Ophthalmology With a Nearly €1 Million Non-dilutive Innovation Grant
BU
Abionyx: reduced net loss in 2023
CF
ABIONYX Pharma Announces Its 2023 Full-Year Financial Results
BU
ABIONYX Pharma SA Reports Earnings Results for the Full Year Ended December 31, 2023
CI
ABIONYX Pharma announces its financial calendar for the year 2024
BU
Abionyx: CSL Behring fails in heart disease trial
CF
ABIONYX Pharma SA Acknowledges the Clinical Results of the Phase 3 Aegis-Ii Study Evaluating the Efficacy and Safety of Csl Behring?S Human-Plasma-Derived Apoa-I, CSL112
CI
Abionyx: former AbbVie executive appointed CMO
CF
ABIONYX Pharma Appoints Rob Scott as Chief Medical Officer and Head of R&D
CI
Abionyx: Successful completion of third GMP batch of CER-001
CF
2,867,986 Ordinary Shares of ABIONYX Pharma SA are subject to a Lock-Up Agreement Ending on 7-DEC-2023.
CI
Abionyx: encouraging results in brain fog
CF
ABIONYX Pharma : Inside Information / Other news releases
PU
ABIONYX Pharma Presents Preclinical Results for CER-001 in Brain Fog, At the 1st International Scientific Congress on Brain-Kidney Interaction in Naples on November 23-24, 2023
CI
Abionyx: promising new results in uveitis
CF
ABIONYX Pharma Announces New Positive Results in a Uveitis Model for the Strategic Development of the First Class of Biomedicines in Ophthalmology Based on its Recombinant apoA-I
CI
Abionyx: cash position reaches 1.7 million euros
CF
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. ABNX Stock
  4. 609 Stock
  5. News ABIONYX Pharma